Curative effect analysis of tiotropium combined with salmeterol fluticasone propionate in medium and heavy bronchial asthma merger chronic obstructive pulmonary disease

Abstract

Objective To explore the clinical effect of tiotropium combined with salmeterol fluticasone propionate in medium and heavy bronchial asthma （asthma） merger chronic obstructive pulmonary disease （COPD）. Methods 126 cases with medium and heavy asthma merger COPD were randomly divided into control group and experience group. Control group were given salmeterol fluticasone propionate inhalation, and experience group were treated with tiotropium combined with salmeterol fluticasone propionate. The change of lung function, time of acute attack, frequency of hospitalization and acute onset of the next interval before and 1 year after treatment were compared between two groups. Results FEV1 , FEV1% pred and FVC after treatment in experience group were superior to that in control group （P〈0.05）. In the follow-up of 1 year, time of acute attack and frequency of hospitalization in experience group were much less than that in control group （ P〈0.05）, and there was no significant different of acute onset of the next interval between two groups （ P〈0.05）. Each dimension and total score of SC-RQ after intervention in experience group were much lower than that in control group （ P〈0.05）. Conclusions Tiotropium combined with salmeterol fluticasone propionate for medium and heavy asthma merger COPD can greatly improve the lung function, clinical effect and patients life quantity. Key words: Bronchial asthma; Chronic obstructive pulmonary disease; Tiotropium